MedTrace Logo

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

NCT02574663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-10-02

No results posted yet for this study

Summary

This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.

Conditions

Interventions

DRUG

TGR-1202

TGR-1202 oral daily dose

DRUG

nab-paclitaxel + gemcitabine

IV infusion

DRUG

Oxaliplatin + Folinic acid + Fluorouracil

IV infusion

DRUG

Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab

IV Infusion

Sponsors & Collaborators

  • SCRI Development Innovations, LLC

    collaborator OTHER

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Johanna Bendell, MD · Sarah Cannon Research Instititue (SCRI)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-11
Primary Completion
2018-08-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02574663 on ClinicalTrials.gov